Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Variations in circulating sex steroid levels in metastatic prostate cancer patients with combined androgen blockade: observation and implication. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1093/jjco/hyh001
10.1093/jjco/hyh001 · External reference
10.1016/j.eururo.2008.10.035
10.1016/j.eururo.2008.10.035 · External reference
10.1016/s0002-9440(10)65160-7
10.1016/s0002-9440(10)65160-7 · External reference
10.1016/s0140-6736(10)61389-x
10.1016/s0140-6736(10)61389-x · External reference
Long‐term endocrine effects of administration of either a non‐steroidal antiandrogen or a luteinizing hormone‐releasing hormone agonist in men with prostate cancer
1993 · External reference
10.1016/j.jsbmb.2009.10.015
10.1016/j.jsbmb.2009.10.015 · External reference
10.2353/ajpath.2009.081107
10.2353/ajpath.2009.081107 · External reference
High‐dose intravenous estrogen therapy in advanced prostatic carcinoma
1989 · External reference
10.1002/pros.10171
10.1002/pros.10171 · External reference
10.1016/j.jsbmb.2007.10.005
10.1016/j.jsbmb.2007.10.005 · External reference
10.1677/joe-07-0470
10.1677/joe-07-0470 · External reference
Adaptation vs selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the dunning R‐3327‐H adenocarcinoma
1981 · External reference
10.1056/nejmoa1001294
10.1056/nejmoa1001294 · External reference
Obesity is associated with castration‐resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database
2011 · External reference
Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen‐independent human prostate cancer cell lines
2009 · External reference
10.1111/j.1464-410x.2004.04803.x
10.1111/j.1464-410x.2004.04803.x · External reference
10.1016/s0022-5347(01)65749-5
10.1016/s0022-5347(01)65749-5 · External reference
10.1016/s0002-9440(10)61676-8
10.1016/s0002-9440(10)61676-8 · External reference
10.1016/j.vph.2011.06.003
10.1016/j.vph.2011.06.003 · External reference
10.1186/1471-2407-10-244
10.1186/1471-2407-10-244 · External reference
EAU guidelines on prostate cancer
2011 · External reference
10.1586/eem.11.20
10.1586/eem.11.20 · External reference
Overall survival benefit and safety profile of radium‐223 chloride, a first‐in‐class alpha‐pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration‐resistant prostate cancer (CRPC) with bone metastases
10.1200/jco.2012.30.5_suppl.8 · 2012 · External reference
10.1056/nejmoa041318
10.1056/nejmoa041318 · External reference
10.1093/jnci/88.13.908
10.1093/jnci/88.13.908 · External reference
10.1002/cncr.26136
10.1002/cncr.26136 · External reference
10.1200/jco.2007.12.4487
10.1200/jco.2007.12.4487 · External reference
Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study
10.1200/jco.2012.30.5_suppl.lba1 · 2012 · External reference
10.1056/nejmoa040720
10.1056/nejmoa040720 · External reference
10.1016/j.eururo.2008.08.033
10.1016/j.eururo.2008.08.033 · External reference
